中药相关肝损伤的风险因素

杨燕; 葛斐林; 黄倩; 曾锐; 张馨月; 孙琴

doi:10.3969/j.issn.1001-5256.2022.05.044

中药相关肝损伤的风险因素

DOI: 10.3969/j.issn.1001-5256.2022.05.044

杨燕^1a,
葛斐林²,
黄倩^1b,
曾锐^1a,
张馨月^1a,
孙琴^{1a, 3, , ,}

1a.
西南医科大学中西医结合学院，四川泸州 646000
1b.
西南医科大学药学院，四川泸州 646000
2.
北京中医药大学中药学院，北京 100029
3.
西南医科大学附属中医医院中西医结合药物研究中心，四川泸州 646000

基金项目:

国家自然科学基金 (81704053);

国家自然科学基金 (8193000309);

全国中药特色技术传承人才培训项目 (T20184828005);

四川省科学技术厅项目 (2021YFH0150);

泸州市人民政府-西南医科大学高层次人才引进专项资助项目 (2017RC-002)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：杨燕、葛斐林负责起草文章; 黄倩、曾锐、张馨月负责收集及分析资料; 孙琴负责拟定写作思路，修改文章关键内容并最后定稿。

详细信息

通信作者:
孙琴，zxyjhsq@swmu.edu.cn

杨燕、葛斐林对本文贡献等同，同为第一作者

计量
- 文章访问数: 785
- HTML全文浏览量: 210
- PDF下载量: 97
- 被引次数: 0
出版历程
- 收稿日期: 2021-09-14
- 录用日期: 2021-10-25
- 出版日期: 2022-05-20

Risk factors for herb-induced liver injury

Yan YANG^1a,
Feilin GE²,
Qian HUANG^1b,
Rui ZENG^1a,
Xinyue ZHANG^1a,
Qin SUN^{1a, 3
, ,
,}

1a.
School of Integrated Traditional Chinese and Western Medicine, Southwest Medical University, Luzhou, Sichuan 646000, China
1b.
School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China
2.
School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China
3.
Drug Research Center of Integrated Traditional Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China

Research funding:

National Natural Science Foundation of China (81704053);

National Natural Science Foundation of China (8193000309);

National Talents Training Project for Characteristic Technical Inheritance of Traditional Chinese Medicine (T20184828005);

Sichuan Provincial Department of Science and Technology Project (2021YFH0150);

Luzhou Municipal People's Government-Southwest Medical University Special Funding Project for the Introduction of High-level Talents (2017RC-002)

More Information

Corresponding author: SUN Qin, zxyjhsq@swmu.edu.cn(ORCID: 0000-0002-4624-8808)

摘要

摘要: 药物性肝损伤是常见的药物不良反应之一，是引起上市后药品撤市的主要原因，越来越引起公众的关注，而中药相关肝损伤(HILI)是其中比较特殊的一种。近年来，HILI事件频发，不仅严重危害患者的健康，而且使得中医药的安全性受到了严重争议。本文将重点从“人”、“药”、“用”三个方面对于HILI的潜在风险因素进行综述，以期为客观厘定和防控HILI提供依据，为构建以肝损伤为代表的中药药物警戒体系提供参考。
- 中草药 /
- 肝损伤 /
- 危险因素 /
- 安全用药
Abstract: Drug-induced liver injury (DILI) is one of the common adverse drug reactions and is the main cause of withdrawal of drugs after marketing, which has attracted more and more attention of the public, and herb-induced liver injury (HILI) is a special type of DILI. In recent years, the frequent occurrence of HILI not only seriously endangers the health of patients, but also causes the controversy over the safety of traditional Chinese medicine. Therefore, this article reviews the potential risk factors for HILI from the three aspects of "patient", "drug", and "use", so as to provide a basis for the objective identification, prevention, and control of HILI and a reference for the construction of traditional Chinese medicine pharmacovigilance system represented by liver injury.
- Drugs, Chinese Herbal /
- Liver Injury /
- Risk Factors /
- Drug Safety

HTML全文

参考文献(47)

[1]	Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1672-5069.2017.02.039. 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1672-5069.2017.02.039.
[2]	GE FL, GUO YM, CAO JL, et al. Research progress in evaluation methods and risk factors for chinese medicines-induced liver injury[J]. Mod Chin Med, 2019, 21(3): 284-290. DOI: 10.13313/j.issn.1673-4890.20180925002. 葛斐林, 郭玉明, 曹俊岭, 等. 中药药源性肝损伤评价方法及风险因素研究进展[J]. 中国现代中药, 2019, 21(3): 284-290. DOI: 10.13313/j.issn.1673-4890.20180925002.
[3]	GE FL, NIU M, HAN ZX, et al. Landscape of hepatobiliary adverse drug reactions related to preparations containing psoraleae fructus and its application in pharmacovigilance[J]. Chin J Integr Med, 2021, 27(11): 832-837. DOI: 10.1007/s11655-021-3442-2.
[4]	GE FL, XUE CM, SUN Y, et al. Advances in pharmacoepidemiology of drug-induced liver injury in China[J]. Chin Hepatol, 2018, 23(11): 1032-1034. DOI: 10.14000/j.cnki.issn.1008-1704.2018.11.029. 葛斐林, 薛春苗, 孙燕, 等. 我国DILI的药物流行病学研究进展[J]. 肝脏, 2018, 23(11): 1032-1034. DOI: 10.14000/j.cnki.issn.1008-1704.2018.11.029.
[5]	GE FL, NIU M, HAN ZX, et al. Analysis of epidemiological characteristics of drug induced liver injury associated with Baixianpi praparations[J]. Chin J Chin Mater Med, 2019, 44(5): 1048-1052. DOI: 10.19540/j.cnki.cjcmm.20181217.001. 葛斐林, 牛明, 韩紫欣, 等. 白鲜皮制剂相关肝损伤的药物流行病学特征分析[J]. 中国中药杂志, 2019, 44(5): 1048-1052. DOI: 10.19540/j.cnki.cjcmm.20181217.001.
[6]	BALLOTIN VR, BIGARELLA LG, BRANDÃO A, et al. Herb-induced liver injury: Systematic review and meta-analysis[J]. World J Clin Cases, 2021, 9(20): 5490-5513. DOI: 10.12998/wjcc.v9.i20.5490.
[7]	TESCHKE R, EICKHOFF A, SCHULZE J, et al. Herb-induced liver injury (HILI) with 12, 068 worldwide cases published with causality assessments by Roussel Uclaf Causality Assessment Method (RUCAM): An overview[J]. Transl Gastroenterol Hepatol, 2021, 6: 51. DOI: 10.21037/tgh-20-149.
[8]	HOOFNAGLE JH, BJÖRNSSON ES. Drug-induced liver injury-types and phenotypes[J]. N Engl J Med, 2019, 381(3): 264-273. DOI: 10.1056/NEJMra1816149.
[9]	XIAO XH, BAI ZF, WANG JB, et al. Traditional chinese medicine safety evaluation and pharmacovigilance[J]. Chin Sci Bull, 2021, 66 (Z1): 407-414. DOI: 10.1360/TB-2020-1034. 肖小河, 柏兆方, 王伽伯, 等. 中药安全性评价与药物警戒[J]. 科学通报, 2021, 66 (Z1): 407-414. DOI: 10.1360/TB-2020-1034.
[10]	BJÖRNSSON ES, BERGMANN OM, BJÖRNSSON HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland[J]. Gastroenterology, 2013, 144(7): 1419-1425, 1425. e1-3; quiz e19-20. DOI: 10.1053/j.gastro.2013.02.006.
[11]	LARREY D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver[J]. Semin Liver Dis, 2002, 22(2): 145-155. DOI: 10.1055/s-2002-30105.
[12]	SHEN T, LIU Y, SHANG J, et al. Incidence and etiology of drug-induced liver injury in Mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241. e11. DOI: 10.1053/j.gastro.2019.02.002.
[13]	KONG X, GUO D, LIU S, et al. Incidence, characteristics and risk factors for drug-induced liver injury in hospitalized patients: A matched case-control study[J]. Br J Clin Pharmacol, 2021, 87(11): 4304-4312. DOI: 10.1111/bcp.14847.
[14]	YANG M, LI ZG, DOU D, et al. Analysis of the status quo of epidemiological research on drug-induced liver injury in mainland China[J]. Chin J Inte Trad West Med Liver Dis, 2020, 30(1): 13-16. DOI: 10.3969/j.issn.1005-0264.2020.01.004. 杨鸣, 李志国, 窦豆, 等. 中国大陆药物性肝损伤流行病学研究的现状分析[J]. 中西医结合肝病杂志, 2020, 30(1): 13-16. DOI: 10.3969/j.issn.1005-0264.2020.01.004.
[15]	DEVARBHAVI H, AITHAL G, TREEPRASERTSUK S, et al. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines[J]. Hepatol Int, 2021, 15(2): 258-282. DOI: 10.1007/s12072-021-10144-3.
[16]	WANG J, MA YY, LIU CH, et al. An epidemiological analysis of drug-induced liver injury based on literature[J]. Chin J Inte Trad West Med Liver Dis, 2019, 29(5): 452-455, 458. DOI: 10.3969/j.issn.1005-0264.2019.05.020. 王静, 马园园, 刘成海, 等. 基于文献的药物性肝损伤流行病学分析[J]. 中西医结合肝病杂志, 2019, 29(5): 452-455, 458. DOI: 10.3969/j.issn.1005-0264.2019.05.020.
[17]	State Drug Administration. Technical guidelines for clinical evaluation of liver injury induced by traditional Chinese medicine[J]. J Clin Hepatol, 2018, 34(7): 1403-1409. DOI: 10.3969/j.issn.1001-5256.2018.07.008. 国家药品监督管理局. 中药药源性肝损伤临床评价技术指导原则[J]. 临床肝胆病杂志, 2018, 34(7): 1403-1409. DOI: 10.3969/j.issn.1001-5256.2018.07.008.
[18]	GAO YJ, ZHAO X, BAI ZF, et al. Prevention and control of safety risk of traditional Chinese medicine based on indirect toxicity cognition Chinese[J]. J Pharm, 2021. https://kns.cnki.net/kcms/detail/11.5219.R.20210825.1438.002.html. 高云娟, 赵旭, 柏兆方, 等. 基于间接毒性认知的中药安全风险防控[J]. 中国药物警戒, 2021. https://kns.cnki.net/kcms/detail/11.5219.R.20210825.1438.002.html.
[19]	WANG Z, XU G, WANG H, et al. Icariside Ⅱ, a main compound in Epimedii Folium, induces idiosyncratic hepatotoxicity by enhancing NLRP3 inflammasome activation[J]. Acta Pharm Sin B, 2020, 10(9): 1619-1633. DOI: 10.1016/j.apsb.2020.03.006.
[20]	GAO Y, WANG Z, TANG J, et al. New incompatible pair of TCM: Epimedii Folium combined with Psoraleae Fructus induces idiosyncratic hepatotoxicity under immunological stress conditions[J]. Front Med, 2020, 14(1): 68-80. DOI: 10.1007/s11684-019-0690-z.
[21]	QIN N, XU G, WANG Y, et al. Bavachin enhances NLRP3 inflammasome activation induced by ATP or nigericin and causes idiosyncratic hepatotoxicity[J]. Front Med, 2021, 15(4): 594-607. DOI: 10.1007/s11684-020-0809-2.
[22]	LI C, RAO T, CHEN X, et al. HLA-B^*3∶ 01 Allele is a potential biomarker for predicting polygonum multiflorum-induced liver injury in humans[J]. Hepatology, 2019, 70(1): 346-357. DOI: 10.1002/hep.30660.
[23]	WANG Z, LIU L, WANG JG, et al. Progress in study of children drug induced liver injury susceptibility based on cytochrome P450[J]. J Shenyang Norm Univ, 2019, 37(1): 20-24. DOI: 10.3969/j.issn.1673-5862.2019.01.004. 王泽, 刘丽, 王建国, 等. 细胞色素P450介导的儿童药物性肝损伤易感性研究进展[J]. 沈阳师范大学学报, 2019, 37(1): 20-24. DOI: 10.3969/j.issn.1673-5862.2019.01.004.
[24]	GUO YM, GE FL, SONG HB, et al. Relative risk analysis of liver-related adverse drug reactions in children based on China's National spontaneous reporting system[J]. J Pediatr, 2021, 234: 85-91. DOI: 10.1016/j.jpeds.2021.03.044.
[25]	YIMER G, AMOGNE W, HABTEWOLD A, et al. High plasma efavirenz level and CYP2B6^*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: A prospective cohort study[J]. Pharmacogenomics J, 2012, 12(6): 499-506. DOI: 10.1038/tpj.2011.34.
[26]	Branch of Hepatobiliary Diseases, China Association of Chinese Medicine, Branch of Chinese Patent Medicine, China Association of Chinese Medicine. Guideline for diagnosis and treatment of herb-induced liver injury[J]. J Clin Hepatol, 2016, 32(5): 835-843. DOI: 10.3969/j.issn.1001-5256.2016.05.003. 中华中医药学会肝胆病分会, 中华中医药学会中成药分会. 中草药相关肝损伤临床诊疗指南[J]. 临床肝胆病杂志, 2016, 32(5): 835-843. DOI: 10.3969/j.issn.1001-5256.2016.05.003.
[27]	FENG HY. Hepatic lesion induced by traditional chinese drug and drug risk management[J]. Chin J Pharm, 2010, 7(6): 356-358. DOI: 10.3969/j.issn.1672-8629.2010.06.012. 冯红云. 浅谈中药致肝损害的现状及其风险管理[J]. 中国药物警戒, 2010, 7(6): 356-358. DOI: 10.3969/j.issn.1672-8629.2010.06.012.
[28]	PENG L, ZHANG L, LI P, et al. Traditional chinese medicine with potential toxicity[J]. Chin J Exper Trad Med Form, 2017, 23(2): 227-234. DOI: 10.13422/j.cnki.syfjx.2017020227. 彭莉, 张林, 李品, 等. 潜在毒性中药探讨[J]. 中国实验方剂学杂志, 2017, 23(2): 227-234. DOI: 10.13422/j.cnki.syfjx.2017020227.
[29]	WANG ZZ. Be wary of the potential liver damage of Polygonum multiflorum and its prescription preparations[J]. Pharm Care Res, 2014, 14(6): 505-506. https://www.cnki.com.cn/Article/CJFDTOTAL-YXFY201406034.htm 王忠壮. 警惕何首乌及其成方制剂的潜在肝损害[J]. 药学服务与研究, 2014, 14(6): 505-506. https://www.cnki.com.cn/Article/CJFDTOTAL-YXFY201406034.htm
[30]	National Adverse Drug Reaction Monitoring Center. Adverse drug reaction information bulletin[J]. Chin J Pharm, 2009, 6(1): 55-56. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYZ201502018.htm 国家药品不良反应监测中心. 药品不良反应信息通报[J]. 中国药物警戒, 2009, 6(1): 55-56. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYZ201502018.htm
[31]	National Adverse Drug Reaction Monitoring Center. Adverse drug reaction information bulletin: Beware of liver damage caused by Zhuanggu Joint Pills[J]. Chin J Ratio Drug Use, 2008, 5(11): 19-20. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYS200811008.htm 国家药品不良反应监测中心. 药品不良反应信息通报: 警惕壮骨关节丸引起的肝损害[J]. 中国执业药师, 2008, 5(11): 19-20. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYS200811008.htm
[32]	ZHNAG L, BAI ZF, LI CY, et al. Study on idiosyncratic liver injury and content of cis-2, 3, 5, 4'-tetrahydroxystilbene-2-O-β-D-glucoside in radix polygoni multiflori preparata[J]. Acta Pharm Sin, 2017, 52(7): 1041-1047. DOI: 10.16438/j.0513-4870.2017-0307. 张乐, 柏兆方, 李春雨, 等. 制首乌中顺式二苯乙烯苷转化量与特异质肝损伤的相关性研究[J]. 药学学报, 2017, 52(7): 1041-1047. DOI: 10.16438/j.0513-4870.2017-0307.
[33]	YE TH. The CT and MR findings of hepatic sinusoidal obstruction syndrome caused by gynura segetum[D]. Wuhan: Huazhong University of Science and Technology, 2013. 叶天和. 土三七致肝窦阻塞综合征的CT及MRI诊断[D]. 武汉: 华中科技大学, 2013.
[34]	SHI WJ, SUN ZG. Overview of liver damage caused by traditional Chinese medicine[J]. Chin J Pract Trad Chin West Med, 2006, 19(13): 1588-1589. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXY200302025.htm 施文杰, 孙志广. 中药所致肝损害概述[J]. 中华实用中西医杂志, 2006, 19(13): 1588- 1589. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXY200302025.htm
[35]	LI CY, HE Q, TANG JF, et al. Metabolomic study on immunological stress-mediated hepatotoxicity of polygonum multiflorum and its processed products of nine times steaming and nine times sunning[J]. Acta Pharm Sin, 2017, 52(7): 1069-1076. DOI: 10.16438/j.0513-4870.2017-0314. 李春雨, 何琴, 唐进法, 等. 免疫应激介导的何首乌"九蒸九晒"炮制减毒作用及代谢组学研究[J]. 药学学报, 2017, 52(7): 1069-1076. DOI: 10.16438/j.0513-4870.2017-0314.
[36]	TU C, JIANG BQ, ZHAO YL, et al. Comparison of processed and crude polygoni multiflori radix induced rat liver injury and screening for sensitive indicators[J]. Chin J Chin Mater Med, 2015, 40(4): 654-660. DOI: 10.4268/cjcmm20150416. 涂灿, 蒋冰倩, 赵艳玲, 等. 何首乌炮制前后对大鼠肝脏的损伤比较及敏感指标筛选[J]. 中国中药杂志, 2015, 40(4): 654-660. DOI: 10.4268/cjcmm20150416.
[37]	WANG JB, LI CY, ZHU Y, et al. Integrated evidence chain-based identification of chinese herbal medicine-induced hepatotoxicity and rational usage: Exemplification by polygonum multiflorum(he shou wu)[J]. Chin Sci Bull, 2016, 61(9): 971-980. DOI: 10.1360/N972015-01289. 王伽伯, 李春雨, 朱云, 等. 基于整合证据链的中草药肝毒性客观辨识与合理用药: 以何首乌为例[J]. 科学通报, 2016, 61(9): 971-980. DOI: 10.1360/N972015-01289.
[38]	ZHANG B. Chinese medicine pharmacovigilance[M]. Beijing: People's Medical Publishing House, 2016. 张冰. 中药药物警戒[M]. 北京: 人民卫生出版社, 2016.
[39]	YANG LM. Comment on traditional medicine prescription[J]. Guangming J Chin Med, 2018, 33(14): 1993-1995. DOI: 10.3969/j.issn.1003-8914.2018.14.005. 杨连梅. 中药处方点评分析[J]. 光明中医, 2018, 33(14): 1993-1995. DOI: 10.3969/j.issn.1003-8914.2018.14.005.
[40]	GU GG. Shennong's Materia Medica[M]. Beijing: People's Medical Publishing House, 1955. 顾观光重辑. 神农本草经[M]. 北京: 人民卫生出版社, 1955.
[41]	WANG B. Yellow empero's canon internal medicine[M]. Beijing: Academy Press, 2004. 王冰. 黄帝内经素问[M]. 北京: 学苑出版社, 2004.
[42]	Branch of Hepatobiliary Diseases, China Association of Chinese, Branch of Chinese Patent Medicine, China Association of Chinese Medicine, Professional Committee of Clinical Chinese Pharmacy, Chinese Pharmaceutical Association, et al. Guidelines for safe use of Polygoni Multiflori Radixl[J]. J Clin Hepatol, 2019, 35(12): 2687-2693. DOI: 10.3969/j.issn.1001-5256.2019.12.009. 中华中医药学会中成药分会, 中华中医药学会肝胆病分会, 中国药学会临床中药学专业委员会, 中国毒理学会临床毒理专业委员会, 中国药理学会药源性疾病学专业委员会肝病分委会, 中南大学临床药理研究所, 中国人民解放军总医院第五医学中心. 何首乌安全用药指南[J]. 临床肝胆病杂志, 2019, 35(12): 2687-2693. DOI: 10.3969/j.issn.1001-5256.2019.12.009.
[43]	XIAO XH. Combination of medicine and pharmacy assists for precise prevention and control of drug-induced liver injury[J]. J Clin Hepatol, 2020, 36(3): 489-490. DOI: 10.3969/j.issn.1001-5256.2020.03.001. 肖小河. 医药结合, 助力药物性肝损伤精准防控[J]. 临床肝胆病杂志, 2020, 36(3): 489-490. DOI: 10.3969/j.issn.1001-5256.2020.03.001.
[44]	JING J, HE TT, WANG RL, et al. Detection of the risk signals of drug-induced liver injury: Challenges and advances[J]. J Clin Hepatol, 2020, 36(3): 491-496. DOI: 10.3969/j.issn.1001-5256.2020.03.002 景婧, 何婷婷, 王睿林, 等. 药物性肝损伤临床风险信号发现: 挑战与进展[J]. 临床肝胆病杂志, 2020, 36(3): 491-496. DOI: 10.3969/j.issn.1001-5256.2020.03.002
[45]	CHI ZC. Research status and progress of drug induced liver injury[J]. World Chin J Dig, 2021, 29(16): 915-925. DOI: 10.11569/wcjd.v29.i16.915. 池肇春. 药物性肝损伤研究现状与进展[J]. 世界华人消化杂志, 2021, 29(16): 915-925. DOI: 10.11569/wcjd.v29.i16.915.
[46]	ZHANG B, LIN ZJ, ZHANG XM. Pharmacovigilance of chinese medicine: Practice of cognition, application, prevention and rescue of drug toxicity[J]. Chin J Chin Mater Medica, 2017, 42(10): 2017-2020. DOI: 10.19540/j.cnki.cjcmm.20170307.007. 张冰, 林志健, 张晓朦. 基于"识毒-用毒-防毒-解毒"实践的中药药物警戒思想[J]. 中国中药杂志, 2017, 42(10): 2017-2020. DOI: 10.19540/j.cnki.cjcmm.20170307.007.
[47]	LI YL, ZHANG B, ZHANG XM, et al. Evaluation and consideration of clinical safety of Traditional Chinese Medicine based on toxic components[J]. Chin J Pharma, 2021, 18(6): 520-524. DOI: 10.19803/j.1672-8629.2021.06.06. 李耀磊, 张冰, 张晓朦, 等. 基于毒害成分的中药临床安全性评价与思考[J]. 中国药物警戒, 2021, 18(6): 520-524. DOI: 10.19803/j.1672-8629.2021.06.06.